Form D · Venture Capital Fund

SV Life Sciences Fund VI, L.P.

Boston, MA · CIK 0001642251

Offering snapshot reported May 26, 2016 · SEC filing

Reported sold: $274M
Investors reported: 24
Minimum accepted: $0
First sale: May 28, 2015

What changed?

Latest filing versus its linked predecessor, where available.

Reported investors0 → 24

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 26, 2016	Amendment	$273,500,000	No comparison	24	SEC filing
May 26, 2015	Initial	Yet to sell	No comparison	0	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.7
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-240550

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Crito Capital LLC	161724

Source: Form D, filed May 26, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

SV LIFE SCIENCES FUND VI, L.P.

Investment adviser: SV HEALTH INVESTORS, LLC

Gross asset value: $201M
Beneficial owners: 37
ADV minimum commitment: $1.5M

Reported in Form ADV on Mar 31, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator JUNIPER SQUARE, INC SAN FRANCISCO, California, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor RSM US LLP BOSTON, Massachusetts, United States

Custodian BANK OF AMERICA, N.A. CHARLOTTE, North Carolina, United States Related to adviser: No

Custodian FIRST-CITIZENS BANK & TRUST COMPANY SANTA CLARA, California, United States Related to adviser: No

Custodian MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED NEW YORK, New York, United States Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: No

RSM US LLP
PCAOB 49

BANK OF AMERICA, N.A.
LEI B4TYDEB6GKMZO031MB27

FIRST-CITIZENS BANK & TRUST COMPANY
LEI L9VVX1KT5TFTKS0MLF66

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
SEC 8-7221

Filing source

Form ADV 2077634 · Mar 31, 2026 · Schedule D 7.B.(1), fund 805-3837790837

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

Related funds

Funds whose names form a numbered series with this one and that share its city or the name of a related person. Form D does not state how these funds are related.

Fund	Latest Form D	Reported sold	Investors
SV LIFE SCIENCES FUND V LP	Mar 10, 2010	$407,226,805	42
SV Life Sciences Fund VI, L.P. (this fund)	May 26, 2016	$273,500,000	24

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Kate Bingham	Executive
Thomas Flynn	Executive
James Garvey	Executive
Eugene Hill	Executive
Paul La Violette	Executive
David Milne	Executive
Michael Ross	Executive
N/A Sv Life Sciences Fund Vi (Gp), L.P.	Executive
N/A Svlsf Vi, Llc	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

C/O Sv Life Sciences Advisers Llc One Boston Place, Suite 3900
Boston, MA, 02108